Aldevron Breakthrough Blog

Rev Up Your R&D

March 12, 2025 by Emily Sether

Speed development using the Breakthrough Booster Program

You’re late for an urgent appointment. Traffic is bumper-to-bumper. Your app shows traffic being backed up for miles. Construction ahead is causing a bottleneck that’s slowing everything to a crawl. Anxiety creeps in as you realize how close you are to being late.

Cars inch forward, taillights glowing like a sea of red lights. A construction crew works on the shoulder, building an obstacle course of orange cones and flashing lights. You feel trapped and frustrated.

Then you see the carpool lane. Other cars, with passengers, are moving into that lane and speeding ahead. Unfortunately, your passenger seat is empty, so you’re left behind.

Shortcut to the carpool lane

Developing a therapeutic in the cell and gene therapy industry has a lot in common with that traffic jam, with plenty of roadblocks: budgetary constraints, technical difficulties, and spending too much of your valuable time (and limited funds) on re-work.

At Aldevron, we want to be your passenger, allowing you to move into the carpool lane and bypass the congestion, noise and frustration that can come along with moving your program through the development pipeline.

Our Breakthrough Booster Program is an exclusive partnership designed to help your team achieve your therapeutic development goals. We will partner with you from the start, removing those barriers impeding your development. That way your team can hit the accelerator and move your program into the fast lane.

When you become part of Booster Program, you receive:

It is free to participate in the Breakthrough Booster Program, and we are excited to bring this level of support to your team as you move out of the traffic jam and into the fast lane for development.

Subscribe to our blog

ABOUT THE AUTHOR

Emily Sether

Emily Sether is the manager of the Inside Sales team at Aldevron, a team focused on providing information that researchers need to be successful while developing tight-knit partnerships between therapeutic developers and the Aldevron team. Prior to supporting life science commercial teams, she was a bench scientist cloning and purifying hundreds of plasmids and proteins, so roadblocks at the bench hit close to home.